RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 78 filers reported holding RECURSION PHARMACEUTICALS IN in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $65,621,903 | -36.4% | 8,749,587 | -15.5% | 0.00% | -40.0% |
| Q1 2024 | $103,212,989 | -13.9% | 10,352,356 | -14.8% | 0.01% | -16.7% |
| Q4 2023 | $119,815,230 | +33.2% | 12,151,646 | +3.4% | 0.01% | +20.0% |
| Q3 2023 | $89,941,723 | +111.3% | 11,757,088 | +106.3% | 0.01% | +150.0% |
| Q2 2023 | $42,563,552 | +0.1% | 5,697,932 | -10.6% | 0.00% | 0.0% |
| Q1 2023 | $42,504,675 | -65.0% | 6,372,515 | -59.5% | 0.00% | -50.0% |
| Q4 2022 | $121,370,172 | +150.4% | 15,741,916 | +245.5% | 0.00% | +33.3% |
| Q3 2022 | $48,473,000 | +180.1% | 4,555,759 | +114.3% | 0.00% | +200.0% |
| Q2 2022 | $17,303,000 | +25.9% | 2,125,732 | +10.8% | 0.00% | 0.0% |
| Q1 2022 | $13,738,000 | -82.8% | 1,918,734 | -58.8% | 0.00% | -75.0% |
| Q4 2021 | $79,770,000 | +110.8% | 4,656,727 | +183.2% | 0.00% | +100.0% |
| Q3 2021 | $37,840,000 | +174.7% | 1,644,494 | +335.7% | 0.00% | +100.0% |
| Q2 2021 | $13,776,000 | – | 377,432 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Data Collective IV GP, LLC | 5,941,120 | $45,806,035 | 48.11% |
| Kinnevik AB (publ) | 7,653,061 | $59,005,100 | 33.28% |
| MV Management XI, L.L.C. | 1,971,908 | $15,203,411 | 26.45% |
| MIC Capital Management UK LLP | 8,451,758 | $65,163,057 | 12.86% |
| ArchPoint Investors | 1,114,626 | $8,593,766 | 4.07% |
| HARVARD MANAGEMENT CO INC | 1,509,254 | $11,636,348 | 1.44% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,710,339 | $20,896,714 | 0.80% |
| Duquesne Family Office | 1,385,950 | $10,685,675 | 0.53% |
| ALLEN OPERATIONS LLC | 217,657 | $1,678,135 | 0.45% |
| Artal Group S.A. | 960,204 | $7,403 | 0.41% |